Pembrolizumab in Patients with Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): Data from the Keynote-013 and Keynote-170 Studies
Year: 2018
Type: conference-abstract
Source: Blood
Authors: Philippe Armand, Scott J Rodig, Vladimir Melnichenko, Catherine Thieblemont, Krimo Bouabdallah, Gayane Tumyan, Muhit Özcan, Sergio Portino, Laura Fogliatto, Dolores Caballero, Jan Walewski, Zafer Gulbas, Vincent Ribrag, Beth A. Christian, Guilherme Fleury Perini, Gilles Andre Salles, Jakub Svoboda, Jasmine M. Zain, Sanjay S Patel, Pei-Hsuan Chen, Azra H. Ligon, Jing Ouyang, Donna S Neuberg, Robert A. Redd, Arkendu Chatterjee, Robert J Orlowski, Arun Balakumaran, Margaret A. Shipp, Pier Luigi Zinzani
Institutions: Dana-Farber Cancer Institute, National Medical and Surgical Center named after N.I. Pirogov, Hôpital Saint-Louis, Université de Bordeaux, Centre Hospitalier Universitaire de Bordeaux, Russian Cancer Research Center NN Blokhin, Ankara University, Hospital del Salvador, Hospital de Clínicas de Porto Alegre, Fundmed Pesquisa, Ensino e Inovacao, Complejo Hospitalario de Salamanca, The Maria Sklodowska-Curie National Research Institute of Oncology, Université Paris-Saclay, Institut Gustave Roussy, The Ohio State University, Hospital Israelita Albert Einstein, Hôpital Lyon Sud, Hospital of the University of Pennsylvania, University of Pennsylvania, City Of Hope National Medical Center, City of Hope, Brigham and Women's Hospital, Merck & Co., Inc., Rahway, NJ, USA (United States), Istituto di Ematologia di Bologna
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2903843213